---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-062918"
form_type: "8-K"
ticker: "KZR"
cik: "0001645666"
company_name: "Kezar Life Sciences, Inc."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T05:15:01.769233+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Kezar Q3 net loss $23.1M; appoints new CEO, restructures to extend cash runway into 2026

## Summary
- Net loss of $23.1M ($0.32/share) vs $17.8M loss in Q3 2022; revenue of $7.0M from Everest upfront.
- Cash, equivalents, marketable securities $218.2M at Sep 30, down from $276.6M at Dec 31, 2022.
- Co-founder Christopher Kirk appointed CEO Nov 7, replacing John Fowler who remains on board.
- Strategic restructuring pauses drug discovery, extends cash runway into late 2026; focuses on zetomipzomib and KZR-261.
- Collaboration with Everest Medicines for zetomipzomib in Greater China, South Korea, SE Asia; Everest joins PALIZADE trial.

## SEC filing metadata
- accession: 0000950170-23-062918
- form_type: 8-K
- ticker: KZR
- cik: 0001645666
- company_name: Kezar Life Sciences, Inc.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645666/000095017023062918/0000950170-23-062918-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645666/000095017023062918/kzr-20231113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-062918
- JSON: https://secwatch.observer/filing/0000950170-23-062918.json
- Plain text: https://secwatch.observer/filing/0000950170-23-062918.txt

## Key facts
- Earnings Releases
  Kezar Life Sciences, Inc. reported financial results for the third quarter ended September 30, 2023.
  - Period: the third quarter ended September 30, 2023
  - Result: reported results
  source text: On November 13, 2023, Kezar Life Sciences, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645666/000095017023062918/0000950170-23-062918-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.